Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference53 articles.
1. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics;Arteaga;Cancer Cell,2014
2. Phase trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer;Bouche;Anticancer Res.,2011
3. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity;Buck;Mol. Cancer Ther.,2006
4. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy;Campbell;Clin. Cancer Res.,2010
5. A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: expansion cohorts;Cervantes-Ruiperez;J. Clin. Oncol.,2012
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Bispecific antibody drug conjugates: Making 1+1>2;Acta Pharmaceutica Sinica B;2024-05
2. Better safe than sorry: dual targeting antibodies for cancer immunotherapy;Biological Chemistry;2024-02-01
3. The Novel IGF-1R Inhibitor PB-020 Acts Synergistically with Anti-PD-1 and Mebendazole against Colorectal Cancer;Cancers;2022-11-23
4. The story of EGFR: from signaling pathways to a potent anticancer target;Future Medicinal Chemistry;2022-09
5. 3D cell culture alters signal transduction and drug response in head and neck squamous cell carcinoma;Oncology Letters;2022-04-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3